Skip to content

Oral Fluid Sars-CoV-2 Ab Rapid test

Rapid point-of-care oral fluid screening test for Sars-CoV-2 antibodies to monitor COVID-19 disease. - O-CovAb

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/025674
Enrollment
100
Registered
2020-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A00-B99- Certain infectious and parasitic diseases Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Diabetes Research Society
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18 years or older, men and women 2. Subjects suspected or with symptoms of Sars-CoV-2 3. Subjects, 3 days after the onset of symptoms 4. Smoking or non-smoking 5. Subjects willing for participating in the study and providing informed consent

Exclusion criteria

Exclusion criteria: Subjects on ventilators or lung support

Design outcomes

Primary

MeasureTime frame
There is a significant positive correlation between presence or absence of (blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms. It is expected to initially observe this relationship most strongly in individuals who have specific disease (RT-PCR confirmed COVID-19 disease) within 7 days of onset, and these antibodies continue to remain positive in recovery period, 21 days and much later for many more weeks.Timepoint: June 16-July 31, 2020

Secondary

MeasureTime frame
(blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms. It is expected to initially observe this relationship most strongly in individuals who have specific disease (RT-PCR confirmed COVID-19 disease) within 7 days of onset, and these antibodies continue to remain positive in recovery period, 21 days and much later for many more weeks.Timepoint: June 16-July 31, 2020

Countries

India

Contacts

Public ContactProf PV Rao

Kumudini Devi Diabetes Research Center

Diabetes@DiaBaid.in9885051110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026